rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ANL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Adlai Nortye at Jefferies conference: pan-RAS push builds toward 2027
      17h agoInvesting.comANLJEF
      Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
      Oct 27Yahoo FinanceANL
      Adlai Nortye director Ji Ping sells $163,274 in ANL stock
      Oct 24Investing.comANL
      Adlai Nortye Enters Clinical Trial Deals With Eli Lilly, Merck KGaA
      Oct 15Yahoo FinanceANL
      Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?

      Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.

      Oct 14Yahoo FinanceANL
      Adlai Nortye Group: Only For The Risk Tolerant After Massive Rally (NASDAQ:ANL)
      Oct 8Seeking AlphaANL
      Yankuang Energy Group Company Limited Sponsored ADR (YZCAY) Upgraded to Buy: Here's Why
      Oct 8Yahoo FinanceANL
      Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

      SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology. “We are pleased to welcome Chris to Adl

      Sep 30Yahoo FinanceANL
      Adlai Nortye director Ji Ping sells $83,150 in shares
      Sep 27Investing.comANL
      Adlai Nortye at Morgan Stanley global healthcare conference: RAS push
      Sep 16Investing.comANLMS
      4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

      Why the AN4035 trial move matters for Adlai Nortye Group stock Adlai Nortye Group (NasdaqGM:ANL) has just dosed the first patient in its global Phase I trial for AN4035 and secured a Study May Proceed letter from the FDA, clearing expansion into the United States. The fresh AN4035 milestone comes after a strong run in Adlai Nortye Group’s stock, with a very large year-to-date share price return and a 1-year total shareholder return of about 8x. Recent 30-day and 90-day share price returns of...

      Sep 15Yahoo FinanceANL
      Jefferies initiates Adlai Nortye stock with buy rating on drug potential
      Sep 10Investing.comANL
      Jefferies Initiates Coverage on Adlai Nortye With Buy Rating, $31 Price Target

      Adlai Nortye (ANL) has an average rating of buy and mean price target of $28.60, according to analys

      Sep 10Yahoo FinanceANL
      Adlai Nortye: A Deep Dive (NASDAQ:ANL)
      Sep 9Seeking AlphaANL
      Lucid Capital Markets initiates Adlai Nortye stock with buy rating
      Sep 8Investing.comANL
      Adlai Nortye doses first patient in AN4035 cancer trial
      Sep 8Investing.comANL
      Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

      First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-May-Proceed" letter SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced tha

      Sep 8Yahoo FinanceANL
      Adlai Nortye Doses First Patient in Phase I Trial for Solid Tumors
      Sep 8Yahoo FinanceANL
      These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts

      Ask any old-school market investor and he’ll tell you that the cliché is true, and ‘past performance cannot guarantee future returns.’ If that were true without exception, then growth investing would not be a viable option – but we all know that investors love to buy into stocks that have shown enormous growth in recent months. The ‘monster growth’ stocks are popular because investing into them is successful. The key is understanding the smart middle way, and treating stocks as individuals, with

      Sep 6Yahoo FinanceANL
      Adlai Nortye's KRAS Opportunity Further Validated by GSK-Hutchmed Deal, Oppenheimer Says
      Sep 4Yahoo FinanceANLHCM
      Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL)

      Detailed price information for Adlai Nortye Group Ltd ADR (ANL-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailANL

      This is the newest page. Registered accounts read further back.